What the DKD Studies TV commercial - Type-2 Diabetes is about.
DKD Studies has recently released a TV spot focused on Type-2 Diabetes. The advertisement features a narrator discussing the risks associated with Type-2 Diabetes and the importance of keeping the condition under control. The spot also highlights the importance of proper management and treatment of the disease, particularly in older adults who may be more susceptible to complications.
Throughout the commercial, DKD Studies emphasizes the need for patients to stay informed about their condition, regularly monitor their blood sugar levels, and work closely with their healthcare provider to manage their symptoms. The ad also encourages patients to consider participating in clinical trials and research studies to help develop new therapies and treatments for Type-2 Diabetes.
Overall, the DKD Studies TV spot is an informative and engaging advertisement that raises awareness about the risks of Type-2 Diabetes and the importance of proper management and treatment. By emphasizing the need for patients to stay informed and take an active role in their care, DKD Studies is helping to empower individuals to live healthier, happier lives despite their diagnosis.
DKD Studies TV commercial - Type-2 Diabetes produced for
MMG
was first shown on television on March 6, 2017.
Frequently Asked Questions about dkd studies tv spot, 'type-2 diabetes'
The prevalence of DKD in most type 2 diabetics - at any point in time - is approximately 30%-50%, and this was reported among US diabetic adults (>90% type 2). This prevalence was ranging between 25% in patients younger than 65 years old to nearly 50% with age older than 65 years (22).
Diabetic kidney disease (DKD) is defined by albuminuria (increased urinary albumin excretion is defined as ≥3.4 mg/mmol [30 mg/g]) and progressive reduction in estimated glomerular filtration rate (eGFR) in the setting of a long duration of diabetes (>10 years' duration of type 1 diabetes; may be present at diagnosis ...
Diabetic kidney disease (DKD) is kidney disease that is due to diabetes. It is also called diabetic nephropathy. Nephropathy means your kidneys aren't working normally. Type 1 and type 2 diabetes are the most common causes of kidney disease. There are 5 stages of DKD.
As proposed by the international organization Kidney Disease Improving Global Outcomes (KDIGO), DKD is used to describe a clinical diagnosis defined by the presence of CKD in a patients with diabetes, whereas the term diabetic nephropathy (DN) is exclusively reserved for the histologic diagnosis of glomerular changes ...
Worldwide prevalence of DKD
DKD is highly prevalent across the globe. The odds of developing CKD in patients with diabetes was reported around 1.75 (95% CI: 1.62–1.89). A cross-sectional study from a risk assessment management program in China found 38.8% prevalence of CKD in 15856 patients with diabetes.
Approximately 1 in 3 adults with diabetes has CKD. Both type 1 and type 2 diabetes can cause kidney disease.
Less than 100 mg/dL (5.6 mmol/L ) is considered healthy. 100 to 125 mg/dL (5.6 to 6.9 mmol/L ) is diagnosed as prediabetes. 126 mg/dL (7 mmol/L ) or higher on two separate tests is diagnosed as diabetes.
Diabetic kidney disease is also called DKD, chronic kidney disease, CKD, kidney disease of diabetes, or diabetic nephropathy.
yours
Pronoun. urs. (Internet slang, text messaging) yours.
It may sometimes be used in texting to mean I don't mind, similar to IDC, or I don't care.
Type 2 diabetes is a common condition that causes the level of sugar (glucose) in the blood to become too high. It can cause symptoms like excessive thirst, needing to pee a lot and tiredness. It can also increase your risk of getting serious problems with your eyes, heart and nerves.
In China, the prevalence of diabetes in the age group 20–79 increased from 4.7% in 1990 to 8.0% in 2019, corresponding to an increase of 71.1% (Fig. S2a). We predicted that the prevalence would further increase from 8.2% in 2020 (∼88.7 million people living with diabetes) to 9.7% (∼108.4 million) in 2030 in China (Fig.
